URGN / UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why

This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the more_horizontal

The consensus price target hints at an 89.6% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric i more_horizontal

UroGen also announced a $120 million private placement to raise funds. The company said it could have its second marketed product as early as next yea more_horizontal

Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers h more_horizontal

UroGen has an approved drug and a platform. However, there's not much growth in revenue. more_horizontal

Shares have lost nearly two-thirds of their value over the past 3 years. RTGel platform is a great fit for bladder cancers due to its ability to allow more_horizontal

UroGen Pharma Ltd. (NASDAQ:URGN ) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Directo more_horizontal

Urogen Pharma Ltd (NASDAQ:URGN ) Q2 2022 Earnings Conference Call August 11, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director, more_horizontal